AnaptysBio, Inc. (ANAB) Deep Dive Video

Summary

AnaptysBio is a newly streamlined royalty vehicle whose upside depends on Jemperli’s oncology growth, Sagard cash-flow reversion, and a decisive legal outcome against GSK/Tesaro.

View ANAB stock page · Read the ANAB research report

Loading the video player…